

BCLC Stage	A (n=2)	B (n=10)	C (n=18)	D (n=1)
Nivolumab	Median (range)			
Months	1	22.3 (1.8-40.1)	7.1 (0.9-21.0)	3.2
Cycles	2	21 (5-83)	12 (2-40)	7
TACE	Median (range)			
Days From Nivolumab to First TACE	-52,-6	8 (-24-122)	-6.5 (-59-190)	-58
Number of TACE Per Patient	1	2 (1-6)	2 (1-6)	1
	Number of patients (percentage)			
Prior Resections	0	7 (70)	6 (33)	0
Prior TACE	0	4 (40)	6 (33)	1 (100)
Prior Sorafenib	0	0	2 (11)	0